Opinion

Video

Shifting Paradigms: Biomarker Testing and ESR1 Mutation Surveillance in HR+ HER2- Breast Cancer

Author(s):

Katherine Clifton, MD,Shipra Gandhi, MD

Dr. Clifton and Dr. Gandhi discuss the critical role of biomarker testing, particularly ESR1 mutation surveillance, in HR+/HER2- breast cancer, and its impact on prognosis and treatment decision-making.

Video content above is prompted by the following:

  • Please discuss the role of biomarker testing, particularly ESR1 mutation surveillance, in HR+/HER2- breast cancer.
  • How do the results of these tests influence prognosis and treatment decision-making?
Related Videos
Alberto Montero, MD
4 experts are featured in this series.
2 expert is featured in this series.
Related Content
Polly Niravath, MD
January 15th 2025

Clinical, Molecular Factors Correlate With pCR for Durvalumab/Trastuzumab/Pertuzumab in Early HER2+ Breast Cancer

Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer
March 3rd 2022

Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer

Ian Krop, MD, PhD, director, Clinical Trials Office, chief clinical research officer, associate director, clinical sciences, Yale Cancer Center; professor, internal medicine (medical oncology), Yale School of Medicine
January 14th 2025

Emerging HER2-Directed Agents May Address Resistance to SOC Regimens in Pretreated HER2+ Breast Cancer

Wainberg Weighs In on Advances in HER2+ GI Cancers
July 12th 2021

Wainberg Weighs In on Advances in HER2+ GI Cancers

peterschreiber.media– stock.adobe.com
December 5th 2024

Chemotherapy-Free Regimen Shows Promise in HER2+/HR+ Metastatic Breast Cancer

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 4th 2024

Disitamab Vedotin Shows Early Efficacy in HER2-Expressing Breast Cancer With PAM Pathway Abnormalities